By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.

Key Statistics

Ownership: Public

Web Site: Alexion
Employees: 1,500
Symbol: ALXN



Company News
Alexion (ALXN) Release: New Data From Global aHUS Registry Presented At ASN 2016 Show A Three-Fold Reduction In Post-Transplant Dialysis In Patients Initiating Soliris (Eculizumab) Treatment Prior To Transplant Compared To Initiating Treatment Post-Transplant 11/18/2016 11:52:13 AM
Alexion (ALXN) Receives NASDAQ Notification Related To The Late Filing Of Form 10-Q 11/17/2016 11:55:43 AM
Alexion (ALXN) Release: New Long-Term Data Presented At American Association for Study of Liver Diseases Show Reduction In Liver Fibrosis And Cirrhosis In A Cohort Of Patients With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma (Sebelipase Alfa) 11/11/2016 11:22:17 AM
Alexion (ALXN) Provides Update On Form 10-Q Filing 11/10/2016 2:45:10 PM
Canceled Appearance at Conference, Late 10Q Filing Fuel Alexion (ALXN) Acquisition Rumors 11/7/2016 6:12:20 AM
Alexion (ALXN) Initiates Simultaneous Registration Trials Of ALXN1210 For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) 10/27/2016 11:46:09 AM
Alexion (ALXN) Reports Third Quarter 2016 Results 10/27/2016 11:27:50 AM
Alexion (ALXN) Release: FDA Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD) 10/20/2016 1:58:38 PM
Alexion (ALXN) To Report Third Quarter 2016 Results On Thursday, October 27, 2016 10/10/2016 9:23:20 AM
Alexion (ALXN) Release: New Long-Term Data Presented At WCPGHAN 2016 Show Rapid And Sustained Improvements In Important Markers Of Liver Injury And Lipid Abnormalities In Children And Adults With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma (Sebelipase Alfa) 10/7/2016 11:38:46 AM